Title:
BLOCKING TYPE PD-L1 SINGLE-DOMAIN CAMEL ANTIBODY AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/158113
Kind Code:
A1
Abstract:
Provided are a programmed death-ligand 1 (PD-L1) single-domain human antibody and an application thereof. According to the present invention, the PD-L1 can be used for treating and/or preventing, or diagnosing PD-L1 related diseases such as tumors by binding to molecules.
Inventors:
WAN YAKUN (CN)
ZHU MIN (CN)
SHEN XIAONING (CN)
GAI JUNWEI (CN)
ZHU MIN (CN)
SHEN XIAONING (CN)
GAI JUNWEI (CN)
Application Number:
PCT/CN2019/075112
Publication Date:
August 22, 2019
Filing Date:
February 14, 2019
Export Citation:
Assignee:
SHANGHAI NOVAMAB BIOPHARMACEUTICALS CO LTD (CN)
International Classes:
A61K39/395; C07K16/28; A61P35/00; C12N15/63
Domestic Patent References:
| WO2017194782A2 | 2017-11-16 |
Foreign References:
| CN1234073A | 1999-11-03 | |||
| CN106939047A | 2017-07-11 | |||
| CN106397592A | 2017-02-15 |
Other References:
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS
ZHU MIN ET AL., NANOSCALE RES LETT., vol. 9, no. 1, 26 September 2014 (2014-09-26), pages 528
See also references of EP 3786184A4
ZHU MIN ET AL., NANOSCALE RES LETT., vol. 9, no. 1, 26 September 2014 (2014-09-26), pages 528
See also references of EP 3786184A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: